

RECEIVED

AUG 23 2001

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC8626CMAS	SERIAL NO. 09803428
APPLICANT William Curatolo, et al.	09803428	
FILING DATE March 9, 2001	GROUP 1616	

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>am</i>	4 5 1 7 3 5 9	5/14/85	Kobrehel et al.	C07H	17/08	
<i>am</i>	4 4 7 4 7 6 8	10/2/84	Bright	A61K	31/71	
<i>am</i>	4 9 6 3 5 3 1	10/16/90	Remington	A61K	31/70	
<i>am</i>	4 7 9 2 4 4 8	12/20/88	Ranade, G. R.	424	438	
<i>am</i>	4 5 2 2 6 2 5	6/11/85	Edgre, D.	604	892	
<i>am</i>	4 9 6 8 5 0 7	11/6/90	Zentner, G. M., et al.	424	465	
<i>am</i>	5 7 4 7 0 5 8	5/5/98	Tipton, et al.	424	423	
<i>am</i>	5 7 0 5 1 9 0	1/6/98	Borad, et al.	424	465	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
<i>am</i>	✓	0	1	0	9	2	5	3	10/14/87	EP	C07H	17/00		
<i>am</i>	✓	8	9	0	2	2	7	1	3/23/89	WO	A61K	31/70		
<i>am</i>	✓	0	3	0	7	1	2	8	3/15/89	EP	A61K	31/71		
<i>am</i>	✓	9	5	0	9	6	0	1	4/13/95	WO	A61K	7/16		
<i>am</i>	✓	9	1	1	7	7	4	4	11/28/91	WO	A61K	9/22		
<i>am</i>		0	2	9	8	6	5	0	1/11/89	EPO	C07H	17/02		
<i>am</i>	✓	9	4	1	2	1	5	9	6/9/94	international	A61K	9/28		
<i>am</i>	✓	9	4	0	0	1	1	2	1/6/94	WO	A61K	9/22		
<i>am</i>		9	1	0	1	1	3	1	2/7/91	WO	A61K	9/22		
<i>am</i>	✓	9	0	0	9	1	6	8	8/23/90	WO	A61K	9/22		
<i>am</i>	✓	0	3	7	8	4	0	4	7/18/90	EP	A61K	31/00		
<i>am</i>	✓	0	0	8	0	3	4	1	7/1/83	EP	A61K	9/22		
<i>am</i>	✓	0	5	8	2	3	9	6	2/9/94	EP	A61K	31/71		
<i>am</i>	✓	2	0	6	6	0	7	0	7/8/81	GB	A61K	9/36		
<i>am</i>	✓	2	0	9	1	0	9	7	7/28/82	GB	A61K	9/36		

RECEIVED

AUG 23 2001



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC8626CMAS	TECH CENTER 1800/2900
	APPLICANT William Curatolo, et al.	09803628
FILING DATE March 9, 2001		GROUP 1616

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>RM</i>		Martindale, The Extra Pharmacopoeia, 30 th , The Pharm. Press, London, 1963, Page 1197
	✓	PDR, 48 th , Med. L994, N.Y. Page 1789
	✓	The Merck Index, 11 th , Merck & Co., N.Y., 1989, Page 146 Remington Pharmaceutical Science, 16 th Merck Pub.
	✓	Farmacia Practica de Remington, second Spanish edition, UTEHA, Mexico, 1965, Pages 471 and 525
	✓	Laegemiddelkataloget, Copenhagen 1992, page 229, and page 356
	✓	Farmaceuten, No. 12, 1990, page 402-405
	✓	Hon-Leung Lee et al., "Drug Properties Influencing The Design of Sustained or Controlled Release Drug Delivery"
	✓	Chapters 88, 90, and 91 from Remington Pharmaceutical Science, 16 th Merck Pub., Co., Pennsylvania (1980), PP. 1535, 1585, 1594.
	✓	Scott Hopkins, The American Journal of Medicine, Volume 91, (Suppl 3A) September 12, 1991, 3A-40S-3A-45S
		J. R. Cardinal, Plenum Publishing Corp., 1984, Drug Release From Matrix Devices
	✓	Richard H. Drew, Pharmacotherapy, Volume 12, Number 3, 1992, pgs 162-173
	✓	Chem. Abstr., Yoshitomi, H., et al., V 119, No. 8, p. 496, abst. no. 79946v, "Evaluation of Enteric Coated Tablet Sensitive to Pancreatic Lipase I. In vitro Disintegration Test"
<i>RM</i>	✓	Farmaceutisk Tidende, No. 35/36, 1988, page 537-548

EXAMINER

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3/25/02